RxDoctor Payments Data

Christopher Ng, MD

Family Medicine · Setauket, NYNPI 1134127616

Payments from drug & device makers

$3,555in general payments, 2019–2025

Across 180 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$994
  • AstraZeneca$674
  • Lilly USA, LLC$287
  • GSK$254
  • Kowa Pharmaceuticals America, Inc.$227
  • Pfizer$214
  • plus $905 from 13 others

What the payments were for

  • Food & beverage$3,539100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,555 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$130,687
Medicare patients
207
Services billed
1,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$36,632
OzempicSemaglutide19$32,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$24,880
Janumet XrSitagliptin Phos/Metformin Hcl18$22,679
ProliaDenosumab11$18,780
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,658
Atorvastatin Calcium128$1,333
Metoprolol Succinate47$1,016
Levothyroxine Sodium46$937
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide29$420
Tamsulosin Hcl27$373
Amlodipine Besylate45$343
Famotidine18$340
Losartan Potassium47$336
Rosuvastatin Calcium29$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$214$36,63227 claims
GSKTrelegy Ellipta, Anoro Ellipta$254$34,53825 claims
Novo NordiskOzempic$994$32,89719 claims
AmgenProlia$57$18,78011 claims
AbbVieSynthroid$73$26813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →